ArticlePediatric blood & cancer2021

A phase 1 study of prexasertib (LY2606368), a CHK1/2 inhibitor, in pediatric patients with recurrent or refractory solid tumors, including CNS tumors: A report from the Children's Oncology Group Pediatric Early Phase Clinical Trials Network (ADVL1515).

Thomas Cash et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.